Top of this page
Skip navigation, go straight to the content
Investor News
- UCB: Solid foundation for sustainable growth 02-Mar-2010
- UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S. 29-Jan-2010
- UCB announces initial clinical trial results involving patients taking certolizumab pegol for moderate to severe Crohn?s disease 21-Dec-2009
- UCB signs a new EUR 1.5 billion credit facility 15-Dec-2009
- UCB completes the placement of 7-year bonds 03-Dec-2009
- UCB launches offering of 7-year bonds 03-Dec-2009
- Ismail Kola joins UCB as Executive Vice President, UCB & President of UCB New Medicines(TM) 10-Nov-2009
